A multicenter, randomized, placebo‐controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy

Purpose:  To evaluate the potential efficacy of levetiracetam as an antiabsence agent in children and adolescents with newly diagnosed childhood or juvenile absence epilepsy.

[1]  P. Ryvlin,et al.  When the past challenges the present: are older antiepileptic drugs still the best choice in childhood absence epilepsy? , 2010, The Lancet Neurology.

[2]  D. Hirtz,et al.  Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. , 2010, The New England journal of medicine.

[3]  E. Vining.  Ethosuximide in childhood absence epilepsy--older and better. , 2010, The New England journal of medicine.

[4]  A. Constanti,et al.  Comparison of the antiepileptogenic effects of an early long‐term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy , 2009, Epilepsia.

[5]  S. Benbadis,et al.  Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: Analysis of two randomized, double-blind, placebo-controlled studies , 2009, Epilepsy Research.

[6]  P. Curatolo,et al.  Levetiracetam in absence epilepsy , 2008, Developmental medicine and child neurology.

[7]  C. Panayiotopoulos,et al.  The significance of specific diagnosis in the treatment of epilepsies , 2008, Developmental medicine and child neurology.

[8]  A. Schulze-Bonhage,et al.  Termination of absence status epilepticus by low‐dose intravenous levetiracetam , 2008, Epilepsia.

[9]  R. Kaminski,et al.  SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy , 2008, Neuropharmacology.

[10]  F. Andermann,et al.  Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures , 2008, Neurology.

[11]  J. Wheless,et al.  Treatment of pediatric epilepsy: European expert opinion, 2007. , 2007, Epileptic disorders : international epilepsy journal with videotape.

[12]  R. Leroy,et al.  Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy , 2007, Neurology.

[13]  F. Marrosu,et al.  Levetiracetam attenuates spontaneous spike-and-wave discharges in DBA/2J mice , 2007, Epilepsy Research.

[14]  F. Onat,et al.  Ethosuximide: from bench to bedside. , 2007, CNS drug reviews.

[15]  P Ryvlin,et al.  Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy , 2007, Neurology.

[16]  E. Posner.  Pharmacological treatment of childhood absence epilepsy , 2006, Expert review of neurotherapeutics.

[17]  R. Raedt,et al.  Chronic levetiracetam treatment early in life decreases epileptiform events in young GAERS, but does not prevent the expression of spike and wave discharges during adulthood , 2005, Seizure.

[18]  M. Manfredi,et al.  Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. , 2005, Epileptic disorders : international epilepsy journal with videotape.

[19]  J. French,et al.  Meta-Analysis and Indirect Comparisons of Levetiracetam With Other Second-Generation Antiepileptic Drugs in Partial Epilepsy , 2005, Clinical neuropharmacology.

[20]  Brigitte M. Bouwman,et al.  Effects of levetiracetam on spike and wave discharges in WAG/Rij rats , 2004, Seizure.

[21]  E. Guarino,et al.  Retrospective Study of the Use of Levetiracetam in Childhood Seizure Disorders , 2004, Journal of child neurology.

[22]  M. Privitera,et al.  Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence. , 2004, Archives of neurology.

[23]  T. Tomson,et al.  Navigating toward Fetal and Maternal Health: The Challenge of Treating Epilepsy in Pregnancy , 2004, Epilepsia.

[24]  Marco Carotenuto,et al.  Lamotrigine versus Valproic Acid as First‐line Monotherapy in Newly Diagnosed Typical Absence Seizures: An Open‐label, Randomized, Parallel‐group Study , 2004, Epilepsia.

[25]  E. Ben-Menachem.  Levetiracetam: treatment in epilepsy , 2003, Expert opinion on pharmacotherapy.

[26]  G. Holmes,et al.  Lamictal (Lamotrigine) Monotherapy for Typical Absence Seizures in Children , 1999, Epilepsia.

[27]  R. Stern,et al.  Lamotrigine‐Associated Rash: Risk/Benefit Considerations in Adults and Children , 1999, Epilepsia.

[28]  J. Ebersole,et al.  Gabapentin in Naive Childhood Absence Epilepsy: Results From Two Double-Blind, Placebo-Controlled, Multicenter Studies , 1996, Journal of child neurology.

[29]  C. Marescaux,et al.  Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy , 1995, Epilepsy Research.

[30]  T. Kurashige,et al.  Proposal for Revised Classification of Epilepsies and Epileptic Syndromes , 1989, No to hattatsu = Brain and development.

[31]  Jorge Eslava‐Cobos,et al.  Experience with the International League Against Epilepsy Proposals for Classification of Epileptic Seizures and the Epilepsies and Epileptic Syndromes in a Pediatric Outpatient Epilepsy Clinic , 1989, Epilepsia.

[32]  H. Hunter.  The treatment of epilepsy. , 1948 .

[33]  E. Perucca.  Designing Clinical Trials to Assess Antiepileptic Drugs as Monotherapy , 2008, CNS drugs.

[34]  L. Lagae,et al.  Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial , 2005, Seizure.

[35]  E. Perucca,et al.  Pharmacological and Therapeutic Properties of Valproate , 2002, CNS drugs.